KOMBINA 10 TAB India - English - Central Drugs Standard Control Organization

kombina 10 tab

dey's - trimethoprim,sulphamethoxazole - tab - 80,400;mg - 10

KOMBINA 60ML SUS India - English - Central Drugs Standard Control Organization

kombina 60ml sus

dey's - trimethoprim,sulphamethoxazole - sus - 40,200;mg;5ml - 60ml

KOMBINA-C 10 TAB India - English - Central Drugs Standard Control Organization

kombina-c 10 tab

dey's - trimethoprim,sulphamethoxazole - tab - 20,100;mg - 10

KOMBINA-F 10 TAB India - English - Central Drugs Standard Control Organization

kombina-f 10 tab

dey's - trimethoprim,sulphamethoxazole - tab - 160,800;mg - 10

Adempas European Union - English - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hypertension, pulmonary - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah) adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva European Union - English - EMA (European Medicines Agency)

efavirenz/emtricitabine/tenofovir disoproxil zentiva

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir

Lopinavir/Ritonavir Mylan European Union - English - EMA (European Medicines Agency)

lopinavir/ritonavir mylan

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

Docetaxel Accord European Union - English - EMA (European Medicines Agency)

docetaxel accord

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w

Nobilis IB 4-91 European Union - English - EMA (European Medicines Agency)

nobilis ib 4-91

intervet international bv - live attenuated avian infectious bronchitis virus variant strain 4-91 - immunologicals for aves - chicken - active immunisation of chickens to reduce the respiratory signs of infectious bronchitis caused by the variant strain ib 4-91.

Ganfort European Union - English - EMA (European Medicines Agency)

ganfort

allergan pharmaceuticals ireland - bimatoprost, timolol - glaucoma, open-angle, ocular hypertension - ophthalmologicals, - reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.